Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019


Dublin, Sept. 26, 2013 (GLOBE NEWSWIRE) -- Research and Markets
( has announced the addition of the "Therapeutic Drug Monitoring Markets" report to their offering.

Therapeutic drug monitoring can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global therapeutic drug monitoring market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.

The "Therapeutic Drug Monitoring" report covers:

  • Chemiluminescence
  • High Pressure Liquid Chromatography (HPLC)
  • Gas Chromatography/Mass Spectrometry
  • Liquid Chromatography/Mass Spectrometry
  • Flucytosine
  • Triazoles
  • Itraconazole
  • Voriconazole
  • Posaconazole
  • Enzyme Immunoassays
  • Enzyme Multiplied Immunoassay Technique
  • Cloned Enzyme Donor Immunoassays
  • Radio Immunoassays
  • Fluorescence Polarization Immunoassays
  • Lateral Flow Immunoassays
  • Particle Enhanced Turbidimetric Inhibition Immunoassays
  • Affinity Chrome Mediated Immunoassays   

Detailed charts with sales forecasts and marketshare data are included.

The "Therapeutic Drug Monitoring" report examines companies manufacturing therapeutic drug monitoring equipment and supplies in the world. Companies covered include:

  • Abbott Laboratories
  • Alere/ Inverness Medical Innovations
  • Bayer AG
  • Beckman Coulter
  • BioChem Pharmaceuticals
  • BioRad
  • OraSure Technologies
  • Roche Diagnostics
  • Siemens Healthcare
  • Thermo Fisher

For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals